
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc. has demonstrated consistent financial growth, highlighted by a 12% year-over-year increase in Cell Processing revenue, reaching $73.5 million in 2024, alongside a sequential revenue growth of 7% to $20.3 million in 4Q24. The company has also raised its FY24 guidance for the Cell Processing platform, projecting revenue between $72 million and $73 million, and is anticipating a further 15% year-over-year increase in FY25 revenue, with projections of $82 million to $85 million. Furthermore, the strong demand for its biopreservation media, coupled with recent divestitures of non-core products aimed at enhancing margins, supports management's expectations of significant revenue and gross margin growth moving forward.
Bears say
BioLife Solutions Inc faces significant risks that could negatively impact its financial performance, including lower-than-expected growth of its products and services as well as challenges in acquiring new customers. The company reported a net loss of $11.4 million, equating to a loss of $0.25 per share, indicating ongoing financial difficulties. Additionally, there are concerns regarding potential disruptions to its manufacturing and supply chain, which could further exacerbate these financial challenges.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares